<DOC>
	<DOC>NCT03002818</DOC>
	<brief_summary>This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in participants with Hepatitis C Virus (HCV) genotype 1 (GT1).</brief_summary>
	<brief_title>Quality of Life Measurement in Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Treatmentnaïve participants Monoinfected participants with chronic hepatitis C virus (HCV) genotype 1 (GT1) Noncirrhotic participants Participants with debilitating fatigue (Fatigue Severity Scale [FSS] greater than or equal to 4) Participants with sources of fatigue other than HCV (especially, severe depression, cancer and hormonal disorders causing clinically significant fatigue) Participants with conditions that do not allow to adhere to protocol and use of the device at investigator's discretion Participants who are wheelchair dependent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ritonavir</keyword>
	<keyword>Chronic Hepatitis C (HCV)</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Sustained Virological Response</keyword>
	<keyword>Ombitasivir</keyword>
	<keyword>Genotype 1</keyword>
</DOC>